Icu Medical Inc. ICUI
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $2.2B | -6% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Gross profit | $822.0M | -0% | FY ending Dec 31, 2025 |
| Operating income | $42.8M | -0% | FY ending Dec 31, 2025 |
| Net income | $732K | +101% | FY ending Dec 31, 2025 |
| Earnings per share | $0.03 | +101% | FY ending Dec 31, 2025 |
| Research & development | $87.5M | -1% | FY ending Dec 31, 2025 |
| Cash from operations | $179.8M | -12% | FY ending Dec 31, 2025 |
| Capital spending | $88.0M | +11% | FY ending Dec 31, 2025 |
| Share buybacks | $8.8M | -27% | FY ending Dec 31, 2025 |
| Cash | $308.0M | -0% | FY ending Dec 31, 2025 |
| Long-term debt | $1.3B | -17% | FY ending Dec 31, 2025 |
| Shareholders' equity | $2.1B | +8% | FY ending Dec 31, 2025 |
| Shares outstanding | 25M | +1% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 13 sales ($8.3M) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Virginia Ruth SanzoneVP, General Counsel | Soldpre-set plan4 fills | 4,856 | $168.69 avg | $819K | Sep 3, 2026 |
| Brian Michael BonnellChief Financial Officer | Soldpre-set plan | 6,381 | $175.00 | $1.1M | Sep 1, 2026 |
| Brian Michael BonnellChief Financial Officer | Soldpre-set plan4 fills | 9,307 | $172.79 avg | $1.6M | Aug 31, 2026 |
| Daniel WoolsonVP, GM-Infusion Capital | Sold | 5,417 | $181.33 | $982K | Aug 13, 2026 |
| Ben SousaChief Information Officer | Sold | 2,250 | $178.32 | $401K | Aug 12, 2026 |
| Christian B. VoigtlanderChief Operating Officer | Sold | 8,929 | $182.93 | $1.6M | Aug 11, 2026 |
| Elisha W FinneyDirector | Sold | 378 | $182.48 | $69K | Aug 11, 2026 |
| Daniel WoolsonPresident | Sold | 2,123 | $132.21 | $281K | May 22, 2026 |
| Virginia Ruth SanzoneVP, General Counsel | Sold | 2,447 | $124.08 | $304K | May 14, 2026 |
| David C. GreenbergDirector | Sold | 2,424 | $122.91 | $298K | May 12, 2026 |
| Daniel WoolsonVP, GM-Infusion Capital | Sold | 2,897 | $152.35 | $441K | Nov 25, 2025 |
| Elisha W FinneyDirector | Sold | 1,285 | $140.42 | $180K | Nov 11, 2025 |
| Virginia Ruth SanzoneVP, General Counsel | Sold | 930 | $142.34 | $132K | Nov 11, 2025 |
Other insider moves (45): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kolleen T KennedyDirector | Option exercise | 1,254 | – | – | May 13, 2026 |
| Laurie HernandezDirector | Option exercise | 1,254 | – | – | May 13, 2026 |
| Elisha W FinneyDirector | Option exercise | 1,254 | – | – | May 13, 2026 |
| Donald AbbeyDirector | Option exercise | 1,254 | – | – | May 13, 2026 |
| David F HoffmeisterDirector | Option exercise | 1,254 | – | – | May 13, 2026 |
| David C. GreenbergDirector | Option exercise | 1,254 | – | – | May 13, 2026 |
| David C. GreenbergDirector | Option exercise | 2,424 | $101.06 | $245K | May 12, 2026 |
| Donald AbbeyDirector | Other | 704 | – | – | Mar 25, 2026 |
| Vivek JainChairman and CEO, Director | Tax withholding2 fills | 12,145 | $125.85 avg | $1.5M | Mar 15, 2026 |
| Christian B. VoigtlanderChief Operating Officer | Tax withholding2 fills | 8,096 | $125.85 avg | $1.0M | Mar 15, 2026 |
| Brian Michael BonnellChief Financial Officer | Tax withholding2 fills | 7,595 | $125.85 avg | $956K | Mar 15, 2026 |
| Virginia Ruth SanzoneVP, General Counsel | Tax withholding2 fills | 4,047 | $125.85 avg | $509K | Mar 15, 2026 |
| Daniel WoolsonVP, GM-Infusion Capital | Tax withholding | 1,295 | $125.85 | $163K | Mar 15, 2026 |
| Ben SousaChief Information Officer | Tax withholding | 718 | $125.85 | $90K | Mar 15, 2026 |
| Christian B. VoigtlanderChief Operating Officer | Option exercise2 fills | 14,648 | – | – | Mar 15, 2026 |
| Daniel WoolsonVP, GM-Infusion Capital | Option exercise | 2,924 | – | – | Mar 15, 2026 |
| Ben SousaChief Information Officer | Option exercise | 1,300 | – | – | Mar 15, 2026 |
| Virginia Ruth SanzoneVP, General Counsel | Option exercise2 fills | 7,324 | – | – | Mar 15, 2026 |
| Vivek JainChairman and CEO, Director | Option exercise2 fills | 21,972 | – | – | Mar 15, 2026 |
| Brian Michael BonnellChief Financial Officer | Option exercise2 fills | 14,648 | – | – | Mar 15, 2026 |
| Vivek JainChairman and CEO, Director | Tax withholding | 59,500 | $132.00 | $7.9M | Mar 8, 2026 |
| Brian Michael BonnellChief Financial Officer | Tax withholding | 39,667 | $132.00 | $5.2M | Mar 8, 2026 |
| Christian B. VoigtlanderChief Operating Officer | Tax withholding | 39,667 | $132.00 | $5.2M | Mar 8, 2026 |
| Virginia Ruth SanzoneVP, General Counsel | Tax withholding2 fills | 14,983 | $132.00 avg | $2.0M | Mar 8, 2026 |
| Daniel WoolsonVP, GM-Infusion Capital | Tax withholding2 fills | 7,507 | $132.00 avg | $991K | Mar 8, 2026 |
| Ben SousaChief Information Officer | Tax withholding2 fills | 4,496 | $132.00 avg | $593K | Mar 8, 2026 |
| Brian Michael BonnellChief Financial Officer | Option exercise | 71,757 | – | – | Mar 8, 2026 |
| Vivek JainChairman and CEO, Director | Option exercise | 107,635 | – | – | Mar 8, 2026 |
| Ben SousaChief Information Officer | Option exercise2 fills | 8,134 | – | – | Mar 8, 2026 |
| Virginia Ruth SanzoneVP, General Counsel | Option exercise2 fills | 27,106 | – | – | Mar 8, 2026 |
| Daniel WoolsonVP, GM-Infusion Capital | Option exercise2 fills | 18,300 | – | – | Mar 8, 2026 |
| Christian B. VoigtlanderChief Operating Officer | Option exercise | 71,757 | – | – | Mar 8, 2026 |
| Christian B. VoigtlanderChief Operating Officer | Tax withholding | 1,946 | $132.00 | $257K | Mar 7, 2026 |
| Virginia Ruth SanzoneVP, General Counsel | Tax withholding | 1,297 | $132.00 | $171K | Mar 7, 2026 |
| Ben SousaChief Information Officer | Tax withholding | 782 | $132.00 | $103K | Mar 7, 2026 |
| Daniel WoolsonVP, GM-Infusion Capital | Tax withholding | 702 | $132.00 | $93K | Mar 7, 2026 |
| Brian Michael BonnellChief Financial Officer | Option exercise | 3,522 | – | – | Mar 7, 2026 |
| Brian Michael BonnellChief Financial Officer | Tax withholding | 1,263 | – | – | Mar 7, 2026 |
| Vivek JainChairman and CEO, Director | Option exercise | 5,282 | – | – | Mar 7, 2026 |
| Vivek JainChairman and CEO, Director | Tax withholding | 2,919 | – | – | Mar 7, 2026 |
| Ben SousaChief Information Officer | Option exercise | 1,409 | – | – | Mar 7, 2026 |
| Virginia Ruth SanzoneVP, General Counsel | Option exercise | 2,348 | – | – | Mar 7, 2026 |
| Daniel WoolsonVP, GM-Infusion Capital | Option exercise | 1,585 | – | – | Mar 7, 2026 |
| Christian B. VoigtlanderChief Operating Officer | Option exercise | 3,522 | – | – | Mar 7, 2026 |
| Elisha W FinneyDirector | Option exercise | 1,285 | $103.76 | $133K | Nov 11, 2025 |
Trades by members of Congress
1 member reported 0 buys and 1 sale since May 6, 2025. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. D | Sold some | $1,001–$15K | May 6, 2025 | Jun 6, 2025 | Self |
Latest SEC filings
- Insider plans to sell 144 · Sep 3, 2026
- Insider plans to sell 144 · Sep 1, 2026
- Insider plans to sell 144 · Aug 31, 2026
- Insider plans to sell 144 · Aug 13, 2026
- Insider plans to sell 144 · Aug 12, 2026
- Insider plans to sell 144 · Aug 11, 2026
- Insider plans to sell 144 · Aug 11, 2026
- Quarterly report 10-Q · Aug 6, 2026
- News filing: Quarterly results 8-K · Aug 6, 2026
- Insider plans to sell 144 · May 22, 2026
- News filing: Bylaws or fiscal year changed, Shareholder vote results 8-K · May 18, 2026
- Insider plans to sell 144 · May 14, 2026
- Insider plans to sell 144 · May 12, 2026
- Quarterly report 10-Q · May 7, 2026
- News filing: Quarterly results 8-K · May 7, 2026
- Shareholder meeting proxy DEF 14A · Apr 2, 2026
- News filing: Executive or board change 8-K · Feb 20, 2026
- Annual report 10-K · Feb 19, 2026
- News filing: Quarterly results 8-K · Feb 19, 2026
- Insider plans to sell 144 · Nov 25, 2025
- Insider plans to sell 144 · Nov 12, 2025
- Insider plans to sell 144 · Nov 12, 2025
- Quarterly report 10-Q · Nov 6, 2025
- News filing: Quarterly results 8-K · Nov 6, 2025
- Quarterly report 10-Q · Aug 7, 2025
About Icu Medical Inc.
Business description
- Industry
- Surgical & Medical Instruments & Apparatus
- Sector
- Industrial Applications and Services
- Headquarters
- San Clemente, CA
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Exchange
- Nasdaq
- Filer size
- Large accelerated filer
- SEC company number (CIK)
- 883984
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.